Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Publisher Name :
Date: 01-Dec-2016
No. of pages: 65

Hepatitis C market has witnessed a historically rare market penetration in terms of the breadth and quality of several strongly innovative and very competitive new products, known as direct-acting antivirals (DAA). The latest DAA combination therapies, such as Harvoni, Zepatier and Epclusa, have been shown to clear hepatitis C virus (HCV) infection in over 90% of treated individuals, demonstrating superior efficacy and tolerability compared with interferon-based therapy and older-generation DAAs.

Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver. Although patients may be asymptomatic for a number of years or decades, chronic HCV infection can lead to liver fibrosis (formation of scar tissue) and ultimately liver cirrhosis, in which permanent fibrotic scar tissue replaces healthy liver cells. In severe cases, cirrhosis may lead to liver failure and death. In addition, hepatitis C patients are at an increased risk of developing liver cancer.

Despite the entry of new therapies, there is a subgroup of patients that do not respond to current treatments, or relapse. In addition, HCV resistance to DAAs may also be a cause for concern, as the development of selection pressure by the host immune system in combination with DAA therapy may lead to outgrowth of resistant viruses. As such, the rationale for investment in first-in-class innovation remains strong.

Recent years have seen a revolution in hepatitis C therapeutic development, and the treatment algorithms have rapidly shifted away from interferon-based therapies and towards interferon-free direct-acting antiviral (DAA) combination therapies. Compared with the older treatments, DAA combination therapies have a favorable safety profile and excellent tolerability and efficacy, achieving cure rates of over 90%.

Although a number of highly effective products have entered the market in the last few years, hepatitis C remains a relatively attractive indication for a number of reasons. There is a large patient population that has unmet needs due to being unresponsive or relapsing following treatment. In addition, the high therapy costs of the newer treatments present a major barrier to care.

The report “Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations” allows you to appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.

In depth, it provides the following:


  • Visualize the composition of the hepatitis C market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.

  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to hepatitis C, all first-in-class targets in the hepatitis C pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 5
2.1 Unmet Needs Remain in Hepatitis C Market 5
2.2 Pipeline Dominated by Direct-Acting Antivirals with Small Number of First-in-Class Products 5
2.3 Diverse Range of Host-Targeting and Direct-Acting Antivirals in First-in-Class Pipeline 5

3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Development Remains Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Disease Symptoms 10
4.3 Epidemiology 10
4.4 Etiology and Risk Factors 11
4.5 Pathophysiology 12
4.6 Disease Progression 14
4.6.1 Acute Stage 14
4.6.2 Chronic Stage 14
4.6.3 End Stage 15
4.6.4 Factors Affecting Progression 15
4.7 Co-morbidities and Complications 15
4.8 Diagnosis 15
4.9 Treatment Options and Treatment Algorithm 16
4.9.1 Treatment Options 16
4.9.2 Treatment Algorithm 18
4.10 Overview of Marketed Products in Hepatitis C 20
4.10.1 Molecule Type and Molecular Target Analysis 20

5 Assessment of Pipeline Product Innovation 21
5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target 21
5.2 Comparative Distribution of Programs between the Hepatitis C Market and Pipeline by Therapeutic Target Family 23
5.3 First-in-Class Programs Targeting Novel Molecular Targets 24
6 Signaling Network, Disease Causation and Innovation Alignment 33
6.1 Complexity of Signaling Networks in Hepatitis C 33
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 34
6.3 First-in-Class Matrix Assessment 34

7 First-in-Class Target Evaluation 37
7.1 Viral Targets 37
7.1.1 Pipeline Programs Targeting HCV P7 37
7.1.2 Pipeline Programs Targeting HCV Envelope Proteins E1 and E2 38
7.1.3 Pipeline Programs Targeting HCV NS4B 40
7.2 Host Targets 41
7.2.1 Pipeline Programs Targeting MicroRNA 122 41
7.2.2 Pipeline Programs Targeting Toll-like Receptor 3 43
7.2.3 Pipeline Programs Targeting Claudin 1 43
7.2.4 Pipeline Programs Targeting Serine C-Palmitoyltransferase 45
7.2.5 Pipeline Programs Targeting Type III Phosphatidylinositol 4-Kinase Beta 45
7.2.6 Pipeline Programs Targeting Caspases 46

8 Strategic Consolidations 50
8.1 Industry-Wide First-in-Class Deals 50
8.2 Licensing Deals 51
8.3 Co-development Deals 54
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 57

9 Appendix 59
9.1 References 59
9.2 Abbreviations 63
9.3 Research Methodology 64
9.4 Secondary Research 64
9.4.1 Market Analysis 64
9.4.2 Pipeline Analysis 64
9.4.3 First-in-Class Matrix Assessment 65
9.4.4 First-in-Class Target Profiles 65
9.4.5 Licensing and Co-Development Deals 65
9.5 Contact Us 65
9.6 Disclaimer 65

List of Tables

Table 1: Hepatitis C Therapeutics Market, Risk Factors for Fibrosis Progression, 2016 15
Table 2: Hepatitis C Therapeutics Market, Global, Characteristics of DAAs, 2016 17
Table 3: Hepatitis C Therapeutics Market, Global, Categories of Approved DAA Therapies in Hepatitis C, 2016 18
Table 4: Hepatitis C Therapeutics Market, Global, AASLD/IDSA Hepatitis C Treatment Guidelines, 2016 19
Table 5: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV P7, 2016 37
Table 6: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV P7, 2016 38
Table 7: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV Envelope Protein E1 and E2, 2016 38
Table 8: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV Envelope Protein E1 and E2, 2016 39
Table 9: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV Envelope Protein E2, 2016 39
Table 10: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV Envelope Protein E2, 2016 39
Table 11: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV NS4B, 2016 41
Table 12: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV NS4B, 2016 41
Table 13: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of MicroRNA 122, 2016 42
Table 14: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting MicroRNA 122, 2016 42
Table 15: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Toll-like Receptor 3, 2016 43
Table 16: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Toll-like Receptor 3, 2016 43
Table 17: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Claudin 1, 2016 44
Table 18: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Claudin 1, 2016 44
Table 19: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Serine C-Palmitoyltransferase, 2016 45
Table 20: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Serine C-Palmitoyltransferase, 2016 45
Table 21: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Type III Phosphatidylinositol 4-Kinase Beta, 2016 46
Table 22: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Type III Phosphatidylinositol 4-Kinase Beta, 2016 46
Table 23: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 1, 2016 47
Table 24: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 2, 2016 47
Table 25: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 3, 2016 47
Table 26: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 5, 2016 48
Table 27: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 6, 2016 48
Table 28: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 7, 2016 48
Table 29: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 8, 2016 48
Table 30: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 9, 2016 49
Table 31: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Caspases, 2016 49
Table 32: Abbreviations 63

List of Figures

Figure 1: Hepatitis C Therapeutics Market, US, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals, 1987-2014 6
Figure 2: Hepatitis C Therapeutics Market, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval ($m), 2006-2013 8
Figure 3: Hepatitis C Therapeutics Market, Major Markets, Hepatitis C Prevalent Population (million), 2015-2022 11
Figure 4: Hepatitis C Therapeutics Market, Major Markets, Hepatitis C Treatment Rate (‘000), 2015-2022 11
Figure 5: Hepatitis C Therapeutics Market, HCV Genomic RNA, 2016 13
Figure 6: Hepatitis C Therapeutics Market, Global, Marketed Products by Molecule Type and Molecular Target, 2016 20
Figure 7: Hepatitis C Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2016 21
Figure 8: Hepatitis C Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 23
Figure 9: Hepatitis C Therapeutics Market, Global, Distribution of Molecular Targets Across Pipeline and Marketed Products, 2016 24
Figure 10: Hepatitis C Therapeutics Market, Global, Distribution of Pipeline First-in-Class and Established Products, 2016 25
Figure 11: Hepatitis C Therapeutics Market, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Stage of Development (%), 2016 25
Figure 12: Hepatitis C Therapeutics Market, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Molecular Target (%), 2016 26
Figure 13: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 1) 27
Figure 14: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 2) 28
Figure 15: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 3) 29
Figure 16: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 4) 30
Figure 17: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 5) 31
Figure 18: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 6) 32
Figure 19: Hepatitis C Therapeutics Market, Global, First-in-Class Molecular Target for Host Factors Matrix Assessment, 2016 35
Figure 20: Hepatitis C Therapeutics Market, Global, First-in-Class Molecular Target for Viral Proteins Matrix Assessment, 2016 36
Figure 21: Hepatitis C Therapeutics Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014 50
Figure 22: Hepatitis C Therapeutics Market, Global, Industry-Wide Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2014 51
Figure 23: Hepatitis C Therapeutics Market, Global, Licensing Deals by Region and Deal Value ($m), 2006-2016 52
Figure 24: Hepatitis C Therapeutics Market, Global, Disclosed and Undisclosed Licensing Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015 52
Figure 25: Hepatitis C Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016 53
Figure 26: Hepatitis C Therapeutics Market, Frequency and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, Global, 2006-2016 54
Figure 27: Hepatitis C Therapeutics Market, Global, Co-development Deals by Region and Deal Value ($m), 2006-2016 55
Figure 28: Hepatitis C Therapeutics Market, Global, Disclosed and Undisclosed Co-development Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015 55
Figure 29: Hepatitis C Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016 56
Figure 30: Hepatitis C Therapeutics Market, Global, Frequency and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2016 57
Figure 31: Hepatitis C Therapeutics Market, Global, First-in-Class Programs with No Recorded Prior Deal Involvement, 2016 58
Figure 32: Hepatitis C Therapeutics Market, Global, First-in-Class Programs with Prior Deal Involvement, 2016 58

  • Global Hepatitis Vaccine Industry Market Research Report
    Published: 13-Aug-2019        Price: US 2960 Onwards        Pages: 105
    The Hepatitis Vaccine market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Hepatitis Vaccine industrial chain, this report mainly elaborates the definition, types, applications and major players of Hepatitis Vaccine market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterprise products, industry dev......
  • Sofosbuvir Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 28-Jul-2019        Price: US 3000 Onwards        Pages: 136
    Sofosbuvir Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Sofosbuvir industry with a focus on the Chinese market. The report provides key statistics on the market status of the Sofosbuvir manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Sofosbuvir market covering all im......
  • Global Hepatitis A Vaccine Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use
    Published: 22-Jul-2019        Price: US 3000 Onwards        Pages: 106
    Summary The report forecast global Hepatitis A Vaccine market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2024. The report offers detailed coverage of Hepatitis A Vaccine industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Hepatitis A Vaccine by geography. The report splits the market size, by volume and v......
  • Global Thymosin a1 Market Insights, Forecast to 2025
    Published: 16-Jul-2019        Price: US 3900 Onwards        Pages: 118
    Thymosins can enhance body immunity and are mainly used in the treatment of hepatitis and tumors. Thymosins mainly include Thymosin, Thymopentin and Thymosin a1. Thymosin a1 is a high-end thymosin. Clinical trials suggest it may be useful in cystic fibrosis, septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, TB, severe acute respiratory syndrome, and lung infections in critically ill patients., and for chronic hepatitis B. It also has been studied fo......
  • Global Hepatitis A Vaccine Market Research Report 2012-2024
    Published: 14-Jul-2019        Price: US 3800 Onwards        Pages: 103
    Summary The global Hepatitis A Vaccine market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as ......
  • Global Prophylactic Hepatitis B Virus Vaccines Market Size, Status and Forecast 2019-2025
    Published: 12-Jul-2019        Price: US 3900 Onwards        Pages: 96
    The main objective of hepatitis B immunization strategies is to prevent chronic hepatitis B virus infection and its serious consequences, including liver cirrhosis and hepatocellular cancer. The increasing prevalence and incidence of hepatitis B infection is the dominant factor of driving the growth of prophylactic hepatitis B virus vaccines market. In 2018, the global Prophylactic Hepatitis B Virus Vaccines market size was xx million US$ and it is expected to reach xx million US$ ......
  • Global Alcoholic Hepatitis Drugs Industry Market Research Report
    Published: 11-Jul-2019        Price: US 2960 Onwards        Pages: 128
    The Alcoholic Hepatitis Drugs market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Alcoholic Hepatitis Drugs industrial chain, this report mainly elaborates the definition, types, applications and major players of Alcoholic Hepatitis Drugs market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterpris......
  • Global Thymosin Alpha 1 Industry Market Research Report
    Published: 11-Jul-2019        Price: US 2960 Onwards        Pages: 131
    The Thymosin Alpha 1 market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Thymosin Alpha 1 industrial chain, this report mainly elaborates the definition, types, applications and major players of Thymosin Alpha 1 market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterprise products, industry develo......
  • Global Hepatitis A Preventive Vaccines Industry Market Research Report
    Published: 11-Jul-2019        Price: US 2960 Onwards        Pages: 139
    The Hepatitis A Preventive Vaccines market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Hepatitis A Preventive Vaccines industrial chain, this report mainly elaborates the definition, types, applications and major players of Hepatitis A Preventive Vaccines market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs